Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

The Up-to-date of Anti-Tuberculosis Treatment

항결핵제의 최신 지견

  • Published : 2006.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001; 163: 1055-58 https://doi.org/10.1164/ajrccm.163.5.2007122
  2. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44 https://doi.org/10.1038/31159
  3. Telenti A. Genetics of drug resistance in tuberculosis. In: Iseman MD, Huitt GA, eds. Clinics in chest medicine. Philadelphia: WB Saunders, 1997: 55-64]
  4. Lew WJ, Park YK, Kim HJ, Chang CH, Bai GH, Kim SK. The proportion of rifabutin-susceptible strains among rifampicin-resistant isolates and its specific rpoB mutations. Tuberc Respir Dis 2005; 59(3): 257-265 https://doi.org/10.4046/trd.2005.59.3.257
  5. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62 https://doi.org/10.1164/rccm.167.4.603
  6. Joia SM, Michael LR, Adrienne RS, J Keith J, Felix AV, Sonya SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-81 https://doi.org/10.1016/S0140-6736(04)15496-2
  7. Tuberculosis Research Centre. Shortening short course chemotherapy: A randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind J Tub 2002; 49: 27-38
  8. Cambau E, Jarlier V. Resistance to quinolones in mycobacteria. Res Microbiol 1996; 147: 52-9 https://doi.org/10.1016/0923-2508(96)80204-X
  9. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 1342-5 https://doi.org/10.1164/rccm.200305-682OC
  10. T.R. Sterling. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int J Tuberc Lung Dis 2004; 8(12): 1396-1400
  11. Shim TS, Seoul Asan Medical Center (personal communication)
  12. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small- molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-66 https://doi.org/10.1038/35016103
  13. Chapter 13. Vaccination to prevent tuberculosis and immunomodulatory therapy for persons with active disease. In: Iseman MD. A Clinician's guide to tuberculosis. Lippincott Williams & Wilkins, 2000: 417-25
  14. Han SK. The up-to-date of tuberculosis treatment. The annual course for respiratology 2002, Hanyang Medical School
  15. Kim EK, Shim TS, Lee JY, Oh YM, Lim CM, Lee SD, et al. The adjuvant effect of subcutaneous Interferon- gamma in the treatment of refractory multidrug- resistant pulmonary tuberculosis. Tuberc Respir Dis 2004; 57: 226-33 https://doi.org/10.4046/trd.2004.57.3.226
  16. Park SK, Jun DS, Lee Y H, Lee DH. Treatment of multidrug-resistant pulmonary tuberculosis with Interferon- gamma subcutaneous injection. Tuberc Respir Dis 2003; 55 (suppl, 2): 84
  17. Koh WJ, Ahn CH, Kim CH, Ahn YM, Lim SY, Seo JY. The therapeutic effect of 6-month inhaled Interferon- gamma treatment in intractible multi-drug resisdtant pulmonary tuberculosis. Tuberc Respir Dis 2001; 51 (suppl, 2): 116
  18. Giosue S, Casarini M, Alemanno L, et al. Effects of aerosolized interferon-$\alpha$in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998; 158: 1156-62 https://doi.org/10.1164/ajrccm.158.4.9803065
  19. Onyebujoh PC, Levin JB, Fourie PB, et al. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354: 116-9 https://doi.org/10.1016/S0140-6736(98)10448-8
  20. Jane MT, Utaiwan U, Anthomy M, Pasakorn A, Margaret B, Sanit M, et al. Thalidomide treatment reduces TNF-$\alpha$ production and enhances weight gain in patients with pulmonary tuberculosis. Molecular Medicine 1995; 1(4): 384-97 https://doi.org/10.1007/BF01556866
  21. Wallis RS, Nsubuga P, Whalen C, Mugerwa RD. Pentoxifylline therapy in HIV-seropositive persons with tuberculosis: a randomized, controlled trial. J Inf Dis 1996; 174: 727-33 https://doi.org/10.1093/infdis/174.4.727
  22. Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Therapy 2005: 1-5
  23. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDA major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci 2000; 97: 13853-8
  24. Hans L Rieder. Interventions for tuberculosis control and elimination. IUATLD 2002, 153-69
  25. Michael H Cynamon. Chemotherapeutic agents for Mycobacterial infections. In: Lloyd N Friedman, ed. Tuberculosis: current concepts and treatment, 2nd edition. CRC Press, 2001: 301-32